Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Callan JMB Inc. (CJMB)
Spring Branch, TX, US
Callan JMB Inc., operating primarily through its subsidiary Coldchain Technology Services, LLC, specializes in providing temperature-controlled logistics solutions specifically for the life sciences sector. The company's services include comprehensive frozen shipping capabilities essential for a wide range of sensitive biological and medical materials. These critical shipments encompass items such as personalized medicines, cell-based therapies, stem cells, cell lines, vaccines, diagnostic samples, reproductive materials (including semen, eggs, and embryos), cord blood, organs, biopharmaceutical products, infectious substances, and other vital commodities. Additionally, Callan JMB Inc. offers packaging services for other perishable (non-pharmaceutical) client goods, alongside technical support. The company was founded in 2006 and is based in Spring Branch, Texas.
Based on only 2 articles — low confidence
- Callan JMB Inc. and Alabama State University Partner to Advance Workforce Development, Research, and Pharmaceutical Innovation at the Atlas Complex Globe News Wire
- Callan JMB Inc. and Alabama State University Partner to Advance Workforce Development, Research, and Pharmaceutical Innovation at the Atlas Complex GlobeNewsWire
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.04% | -10.62% | -15.83% | -31.76% | -72.99% | -9.01% | -81.57% | -74.75% | -74.75% | -74.75% | -74.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Integrated Freight & Logistics: +6.5%-12.8% Q1'26: -23.7% (vs Q1'25)
-
EPS growth Integrated Freight & Logistics: +7.1%-109.2% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Integrated Freight & Logistics: +60.0%-138.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Integrated Freight & Logistics: +6.9%-139.2% Q1'26: +0.0% (vs Q1'25)
-
ROIC Integrated Freight & Logistics: +6.4%-362.3% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Integrated Freight & Logistics: +0.1%+66.5% Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Integrated Freight & Logistics: 0.95×-0.26× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 4.8K | 0.05% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Croyle David J | Officer / 10% Owner | P-Purchase | A | Common Stock | 10,195 | 1.75 | 17.8K | 800,000 | I | ↗ |
| 2026-03-06 | Croyle David J | Officer / 10% Owner | P-Purchase | A | Common Stock | 14,805 | 1.76 | 26.1K | 789,805 | I | ↗ |
| 2025-12-30 | Dial Gerald | Director | P-Purchase | A | Common Stock | 461 | 1.22 | 562.42 | 461 | D | ↗ |
| 2025-12-16 | Williams Wayne D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 1.73 | 8.7K | 84,355 | I | ↗ |
| 2025-12-15 | Williams Wayne D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,810 | 1.70 | 18.4K | 79,355 | I | ↗ |
| 2025-12-12 | Williams Wayne D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 4,926 | 1.75 | 8.6K | 2,267,488 | D | ↗ |
| 2025-12-11 | Williams Wayne D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 30,856 | 1.65 | 50.9K | 68,545 | I | ↗ |
| 2025-12-10 | Williams Wayne D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 13,689 | 1.65 | 22.6K | 38,689 | I | ↗ |
| 2025-12-09 | Duke Liberty Smith | Director | P-Purchase | A | Common Stock | 612 | 1.52 | 930.24 | 1,512 | D | ↗ |
| 2025-12-08 | Duke Liberty Smith | Director | P-Purchase | A | Common Stock | 900 | 1.56 | 1.4K | 900 | D | ↗ |
| 2025-02-04 | Duke Liberty Smith | Director | A-Award | A | Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-02-04 | Dial Gerald | Director | A-Award | A | Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | D | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Wayne Williams, Chief Executive Officer, President, and Chairman of the Board | — | — | — | — | — | — | 2.97M | 0.00% | ↗ |
| 2 | 2024 | David J. Croyle, M.D., Chief Medical Officer | — | — | — | — | — | — | 832.1K | 0.00% | ↗ |
| 3 | 2024 | Jeffrey Appleman, Former Chief Financial Officer | — | — | — | — | — | — | 171.7K | 0.00% | ↗ |
| 4 | 2024 | Eric Kash, Executive Vice President and Director | — | — | — | — | — | — | 102.9K | 0.00% | ↗ |
| 5 | 2024 | Christopher Shields, Interim Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wayne Williams | Founder, Chief Executive Officer, President & Chairman | 541.1K | male |
| Eric L. Kash | Executive Vice President & Director | 208.4K | male |
| Christopher Shields | Interim CFO & Senior VP of Governmental Affairs and COO | 150.2K | male |
| David J. Croyle | Chief Medical Officer | 87.7K | — |
| Wiliam McBride | Chief Information Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CJMB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
